Intercell and Kirin enter strategic alliance to develop antibodies for the treatment of severe pneumococcal infections

10-Apr-2006

Intercell AG announced that it has entered into a strategic alliance with Kirin Brewery Co. Ltd. (Japan) to develop human monoclonal antibodies against severe infections caused by Streptococcus pneumoniae. Under the agreement, Kirin obtains global rights to develop and commercialize antibodies directed against antigens that have been detected by Intercells proprietary Antigen Identification Program (AIP®). This technology identifies antigens that are protective in vaccines, but are also suitable targets for blocking the pathogens infectivity. The parties will collaborate in the preclinical development of the product, with Kirin being responsible for the clinical development, registration and marketing of the product.

Over the term of the agreement, Intercell is entitled to milestone payments totaling at approximately EUR 40 million, including an upfront payment of EUR 4 million, and will receive significant royalties on future net sales of the product. In addition, Intercell will be compensated for its development contributions.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous